23/03/2026
The science is proven. The product is selling. Now the raise is open. 🧬💚
life, the Australian biotech company commercialising patented branched-fat technology, is officially live for investment on Swarmer.
Becoming cash flow positive in June 2025, Adepa is reaching new milestones:
✅ $70K+ in monthly revenue.
✅ 20,000+ customers served.
✅ Validated results for IBS symptoms.
✅ Patented IP.
✅ Expansion plans into children's health, pet nutrition & skincare.
Traditional prebiotics fail to improve gut health symptoms for up to 80% of users. Adepa is introducing a breakthrough ingredient that has been shown to turn non-responders into responders, and with the global probiotics market valued at $84 billion USD, it's clear why investors are excited!
Become a shareholder today on Swarmer:
https://swarmer.com.au/en/company/adepa/overview/
Always consider the CSF Risk Warning and Offer Document before investing.